with lower respiratory tract infections in the winter. 2 Although the pathogenesis of RSV Background -Experimental and clinical bronchiolitis is not fully understood, increasing evidence suggests that respiratory synexperimental evidence suggests that the host cytial virus (RSV) bronchiolitis is an imimmune response plays an important role. 2 3 In mune mediated disease. Corticosteroids addition, both pathological and clinical analogy might therefore be effective in the treatexists between RSV bronchiolitis and childhood ment of RSV bronchiolitis.
Characteristics of the patients at entry to the study Prednisolone (n=27) Placebo (n=27)
Median (IQR) age (months) 3.3 (1.4-5.9) 3.9 (1.9-6.1) Sex (F:M) 9:18 16:11 Family history of atopy 9 10 Risk group * 6 9 Mean (SD) log IgE 0.7 (0.3) 1.1 (0.7) Median (IQR) symptom score 5.5 (4.0-7.0) 5.5 (3.5-7.0) * Risk group=patients with congenital heart disease, bronchopulmonary dysplasia, or ex-premature patients. macy using blinded sealed envelopes, the 5-7 kg, etc). The study treatment was oral prednisolone powder (1 mg/kg/day in two divided doses for seven days) or placebo, de-error ( ) set at 0.05, the required study population of non-ventilated patients was 20 evalulivered as identical capsules, which were broken and dissolved in water. Treatment was started able patients in each group.
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In the ventilated patients duration of mechwithin 24 hours of admission. If a patient vomited within 60 minutes after intake, a repeat anical ventilation and duration of hospital stay were used to evaluate efficacy. dose was given. The decision to treat patients with supplemental oxygen, bronchodilators, or antibiotics, or to discharge them, was at the discretion of the attending physician, in-  Statistical analyses were performed with the dependent of the investigators.
SPSS/PC+ package, version 5.0.2. (SPSS Inc). For normally distributed data the Student's t test was used to compare group means,   For the efficacy analysis patients were divided otherwise the Mann-Whitney U test was applied. Proportions were compared by the 2 into two groups depending on whether or not they were on mechanical ventilation at the time test. Values are expressed as mean (SE) unless stated otherwise. A two sided p value of <0.05 of entry into the study. In the non-ventilated patients a daily recorded standardised symptom was considered statistically significant. score, as described previously, 10 and the duration of the stay in hospital were used as outcome variables. The symptom score evaluated Results
During three seasons 54 children were enrolled four items: respiratory rate, presence of wheezing, presence of cyanosis, and the use of ac-into the study of which 27 were randomised to receive prednisolone and 27 placebo. The cessory respiratory muscles. Each of these items was scored on an ordinal scale from 0 (normal characteristics of the patients at entry to the study did not differ significantly between the or none) to 3 (severe). The symptom score therefore ranged from 0 (no symptoms) to two groups (table 1) .
Forty patients (20 in each group) were not 12 (severe bronchiolitis). Patients were scored when quietly awake and at the same time of day. on mechanical ventilation at entry to the study.
Two of these (both on placebo) needed mechOnly two investigators performed the scoring (JBMvW, TFWW) and each patient was scored anical ventilation after the start of the study medication, one patient after one day and the throughout the study by the same investigator. For each patient the symptom score was plotted other after three days. Since change over three days in non-ventilated patients was the inagainst time. The slope of the regression line through these points, representing the mean tended end point of our study, the first patient was omitted from the efficacy analysis. daily decrease in the symptom score (points/ day), was used in the statistical analysis.
17 ClinThe course of the symptom score of the remaining 39 non-ventilated patients is shown ical experience had shown that most children with acute bronchiolitis have recovered after in fig 1. During the first three days of treatment the symptom score decreased significantly seven days so that a difference in symptom scores between treatment groups by that day faster in the prednisolone group (−1.2 (0.2) points/day) than it did in the placebo group would no longer be discernible. We hypothesised before the study that the largest (−0.6 (0.2) points/day; 95% confidence interval (CI) for difference=−1.2 to −0.1, p= difference, if any, between treatment groups would be observed half way between the start 0.02). The length of time in hospital was one day shorter in the prednisolone group than of the study (day 0) and full recovery (day 7) -that is, on day 3. It was felt that a difference in the placebo group; this difference was not significant (7.3 (1.2) versus 8.3 (0.9) days, of at least one point in the clinical score between groups on day 3 would be clinically relevant. respectively, 95% CI for difference=−4.1 to 2.2, p=0.54). We observed a trend towards Using a power calculation, estimating the SD of the symptom score to be 1, and wishing to greater treatment benefit in patients with more severe bronchiolitis (symptom score >6 at detect a difference in symptom scores between groups of 1, with 90% power and the type I entry): the mean decrease of the symptom
score in the first 3 days of treatment was −1.8 to RSV -that is, interferon is found in significantly lower amounts in the nasopharynx (0.2) points/day in the prednisolone group and −0.8 (0.3) points/day in the placebo group. of children with RSV infections than in children with parainfluenza or influenza virus In order to determine whether the effect of treatment was dependent on the severity of infections.
19 20 Recently, De Boeck et al demonstrated no effect of corticosteroids on microsymptoms at entry we performed an analysis of variance modelling the effects of treatment, biologically confirmed RSV bronchiolitis. 12 In this study, however, patients belonging to risk baseline severity score, and the interaction between the two. Only treatment entered the groups for severe RSV bronchiolitis were excluded because of alternative treatment. In our model significantly (F=4.96, p=0.03), whereas neither baseline severity score (F= study there was a trend towards a greater beneficial effect of steroid therapy in more severely 1.03, p=0.31) nor the interaction term (F= 0.06, p=0.81) contributed significantly. affected children. This trend, however, was not statistically significant. In addition, our study Fourteen patients (seven in each group) were on mechanical ventilation at entry into the was not specifically designed to answer this question. The observed trend would suggest study. One girl with bronchopulmonary dysplasia died three weeks after admission as a that additional studies on the effect of steroid treatment in infants with severe RSV bronresult of respiratory failure. She had received placebo. The duration of mechanical vent-chiolitis are warranted.
RSV alone is not sufficient to cause disease, ilation was 1.6 days shorter in the prednisolone group (4.7 (1.1) days) than in the placebo and increasing evidence suggests that the immune response to RSV leading to airway group (6.3 (1.6) days), 95% CI for difference= −5.8 to 2.7, p=0.56. None of the patients in inflammation contributes considerably to illness. 2-5 21-23 Corticosteroids may reduce this either group needed to be re-intubated due to upper respiratory tract symptoms resulting airway inflammation. 24 Airway inflammation in children is difficult to study. The symptom from intubation. The duration of stay in hospital was six days shorter in the prednisolone score that we and others used is obviously an insensitive method for assessing improvement group (11.0 (0.7) days) than in the placebo group (17.0 (2.0) days), 95% CI for differ-in lung function. In children with a low pretreatment score the symptom score is especially ence=−10.2 to −1.8, p <0.01.
Neither a positive family history for atopic less sensitive than in children with a higher pretreatment score. disease nor the total IgE level of the patients at entry to the study confounded the effect of Further study should focus on more sensitive measurements of airway inflammation, such prednisolone. There was no significant difference in the duration of supplemental oxygen, as cell or cytokine profiles in bronchoalveolar lavage fluid, to measure more directly the effect the use of bronchodilators, or the proportion of patients who received antibiotics between of corticosteroids.
The beneficial effects of corticosteroids the two groups.
should be weighed against their side effects. In the present study no clinical significant side effects of prednisolone were found. This is in Discussion The results of this study suggest that systemic accordance with previous studies regarding the safety of short courses of oral steroids corticosteroids may be effective in accelerating the clinical recovery of children admitted to for asthma exacerbations and croup in children. 25-27 Viral shedding may be prolonged by hospital with RSV bronchiolitis. Patients who were treated with prednisolone showed a sig-corticosteroids. 28 However, the clinical and epidemiological consequences of a possible pronificantly faster clinical improvement, although the beneficial effect of prednisolone was rel-longed period of viral shedding in the limited group of patients who need to be admitted atively small. Ventilated patients who were treated with prednisolone were admitted to to hospital with severe RSV bronchiolitis are probably small. hospital for a considerably shorter duration than patients in the placebo group.
In conclusion, this study shows that prednisolone is effective in accelerating the clinical Several investigators have studied the effect of corticosteroids in children with bron-recovery of children admitted to hospital with RSV bronchiolitis. The effect is limited and chiolitis, but results are inconsistent. [9] [10] [11] [12] [13] [14] Studies that demonstrated a beneficial effect more studies are required to evaluate the role of steroid therapy in these infants. had an inhomogeneous study population 10 or numbers were small. 10 14 Three other studies 
